Anti-IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels.

[1]  J. Parkin,et al.  Treatment of patients with the hypereosinophilic syndrome with mepolizumab. , 2008, The New England journal of medicine.

[2]  S. Phipps,et al.  Eosinophil trafficking in allergy and asthma. , 2007, The Journal of allergy and clinical immunology.

[3]  M. Collins,et al.  Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis. , 2006, The Journal of allergy and clinical immunology.

[4]  James J. Lee,et al.  Schistosoma mansoni infection in eosinophil lineage-ablated mice. , 2006, Blood.

[5]  H. Simon,et al.  Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report. , 2006, The Journal of allergy and clinical immunology.

[6]  T. Haverty,et al.  Rebound eosinophilia after treatment of hypereosinophilic syndrome and eosinophilic gastroenteritis with monoclonal anti-IL-5 antibody SCH55700. , 2004, The Journal of allergy and clinical immunology.

[7]  T. Haverty,et al.  Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome. , 2004, Blood.

[8]  M. Rothenberg.  Eosinophilic gastrointestinal disorders (EGID). , 2004, The Journal of allergy and clinical immunology.

[9]  J. Boyce,et al.  Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes. , 2004, The Journal of allergy and clinical immunology.

[10]  J. Ring,et al.  Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. , 2003, The New England journal of medicine.

[11]  S. Phipps,et al.  Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. , 2003, The Journal of clinical investigation.

[12]  D. Postma,et al.  Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. , 2003, American journal of respiratory and critical care medicine.

[13]  Peter Marynen,et al.  A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. , 2003, The New England journal of medicine.

[14]  A. Kay,et al.  Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. , 2003, American journal of respiratory and critical care medicine.

[15]  M. Rothenberg,et al.  Receptor internalization is required for eotaxin-induced responses in human eosinophils. , 2003, The Journal of allergy and clinical immunology.

[16]  M. Rothenberg,et al.  IL-5 Promotes Eosinophil Trafficking to the Esophagus1 , 2002, The Journal of Immunology.

[17]  D. Marmer,et al.  Perforin expression in cytotoxic lymphocytes from patients with hemophagocytic lymphohistiocytosis and their family members. , 2002, Blood.

[18]  A. Straumann,et al.  Idiopathic eosinophilic esophagitis is associated with a T(H)2-type allergic inflammatory response. , 2001, The Journal of allergy and clinical immunology.

[19]  M. Rothenberg,et al.  An etiological role for aeroallergens and eosinophils in experimental esophagitis. , 2001, The Journal of clinical investigation.

[20]  K. Chung,et al.  Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsìveness, and the late asthmatic response , 2000, The Lancet.

[21]  K. Willard-Gallo,et al.  Clonal Th2 lymphocytes in patients with the idiopathic hypereosinophilic syndrome , 2000, British journal of haematology.

[22]  J. Vandekerckhove,et al.  Interleukin 5 regulates the isoform expression of its own receptor alpha-subunit. , 2000, Blood.

[23]  C. Davis,et al.  Pharmacokinetics and pharmacodynamics of SB-240563, a humanized monoclonal antibody directed to human interleukin-5, in monkeys. , 1999, The Journal of pharmacology and experimental therapeutics.

[24]  S. Bel,et al.  Differential regulation of eosinophil chemokine signaling via CCR3 and non-CCR3 pathways. , 1999, Journal of immunology.

[25]  R. Dummer,et al.  Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. , 1999, The New England journal of medicine.

[26]  P. Foster,et al.  Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model , 1996, The Journal of experimental medicine.

[27]  F. Finkelman,et al.  Anti-cytokine antibodies as carrier proteins. Prolongation of in vivo effects of exogenous cytokines by injection of cytokine-anti-cytokine antibody complexes. , 1993, Journal of immunology.

[28]  D. Jones.  The eosinophil. , 1993, Journal of comparative pathology.

[29]  B. Andresen,et al.  Internalization, lysosomal degradation and new synthesis of surface membrane CD4 in phorbol ester-activated T-lymphocytes and U-937 cells. , 1992, Experimental cell research.

[30]  C. Sanderson,et al.  Interleukin-5, eosinophils, and disease. , 1992, Blood.

[31]  M. Tsujimoto,et al.  Structure of recombinant human interleukin 5 produced by Chinese hamster ovary cells. , 1990, Journal of biochemistry.

[32]  R. Coffman,et al.  In vivo administration of antibody to interleukin-5 inhibits increased generation of eosinophils and their progenitors in bone marrow of parasitized mice. , 1990, Blood.

[33]  M. Samoszuk,et al.  Detection of interleukin-5 messenger RNA in Reed-Sternberg cells of Hodgkin's disease with eosinophilia. , 1990, Blood.

[34]  A. Sheffer,et al.  Interleukin 5 and phenotypically altered eosinophils in the blood of patients with the idiopathic hypereosinophilic syndrome , 1989, The Journal of experimental medicine.

[35]  W. Solbach.  Brief Definitive Report TUMOR-PROMOTING PHORBOL ESTERS SELECTIVELY ABROGATE THE EXPRESSION OF THE T4 DIFFERENTIATION ANTIGEN EXPRESSED ON NORMAL AND MALIGNANT (SI),ZARY) T HELPER LYMPHOCYTES* , 2003 .